Autoaggregation-associated carbapenem tolerance mediated by mrkH inactivation identified from a cohort of Klebsiella pneumoniae species complex clinical isolates
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Natsuki Yamanaka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infection Control Science, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8675, Japan. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Anti-Bacterial Agents, Carbapenems. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: JST, SPRING, AMED-CREST.
Abstract (Originalsprache)
Objective
The objective of this study is to elucidate the phenotypic and genetic basis of carbapenem tolerance in Klebsiella pneumoniae species complex bloodstream isolates lacking carbapenemase genes, with a focus on multicellular behaviours. Materials and methods Fifty clinical K. pneumoniae species complex isolates from bloodstream infections were screened for reduced susceptibility to meropenem. Five strains (MIC 1–2 mg/L) lacking carbapenemase genes were analysed using whole-genome sequencing, time-kill assays, plasmid-based gene expression assays and phenotypic assays, including autoaggregation and biofilm formation.
Results
The results of the time-kill assay showed that three strains were carbapenem tolerant. Two strains carrying blaDHA-1 exhibited reduced meropenem activity and enhanced survival following drug exposure. One isolate showed sustained survival and carried a frameshift mutation in mrkH, leading to downregulation of mrkA expression and enhanced autoaggregation. Complementation with wild-type mrkH reduced tolerance. Disruption of cellular aggregates significantly decreased survival, indicating that aggregation provides physical protection against meropenem.
Conclusions
This study identified mrkH-linked autoaggregation as a novel mechanism of carbapenem tolerance in Klebsiella isolates. Overall, the findings underscore the role of multicellular behaviours in antibiotic resilience and highlight the potential clinical relevance of non–carbapenemase-mediated tolerance mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infection Control Science, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8675, Japan.
- Medical Mycology Research Center, Chiba University, Chiba 260-8673, Japan.
- Plant Molecular Science Center, Chiba University, Chiba 260-8675, Japan.
- Department of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.
- Division of Clinical Laboratory, Chiba University Hospital, Chiba 260-8677, Japan.
ORCID-Profile: Natsuki Yamanaka, Hiroki Takahashi, Akiko Takaya
Förderung
- JST
- SPRING
- AMED-CREST
Zitieren
APA
Yamanaka, N., Takahashi, H., Takahashi, N., Saito, H., Yamamoto, R., Kusuya, Y., Murata, S., Matsushita, K., Nakada, T. A., & Takaya, A. (2026). Autoaggregation-associated carbapenem tolerance mediated by mrkH inactivation identified from a cohort of Klebsiella pneumoniae species complex clinical isolates. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag017
Vancouver
Yamanaka N, Takahashi H, Takahashi N, Saito H, Yamamoto R, Kusuya Y, et al. Autoaggregation-associated carbapenem tolerance mediated by mrkH inactivation identified from a cohort of Klebsiella pneumoniae species complex clinical isolates. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag017
BibTeX
@article{Yamanaka2026,
author = {Yamanaka, Natsuki and Takahashi, Hiroki and Takahashi, Nozomi and Saito, Hina and Yamamoto, Ryoya and Kusuya, Yoko and Murata, Shota and Matsushita, Kazuyuki and Nakada, Taka-Aki and Takaya, Akiko},
title = {Autoaggregation-associated carbapenem tolerance mediated by mrkH inactivation identified from a cohort of Klebsiella pneumoniae species complex clinical isolates},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag017}
}
EUVIMED